In Vitro Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Clinical Isolates of Meropenem-Non-Susceptible Pseudomonas aeruginosa: A Two-Center Study.

•Susceptibility rates for ceftazidime-avibactam (C/A) and ceftolozane-tazobactam (C/T) were similar (83.3% for C/A and 82.4% for C/T).•The beta-lactam resistance pattern of isolates had an effect on activity of C/A and C/T.•C/T MICs were generally lower than C/A MICs for Pseudomonas aeruginosa isolates.